- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Primary progressive multiple sclerosis (PPMS)
- Meeting Date: July 2020
- Public Summary Document (PSD) July 2020 PBAC Meeting - (PDF 1314KB)
- Public Summary Document (PSD) July 2020 PBAC Meeting - (Word 95KB)
Ocrelizumab – July 2020
Ocrelizumab: Solution concentrate for I.V. infusion 300 mg in 10 mL; Ocrevus®
Last updated
30 October 2020